MX2022001505A - Composiciones de trofinetida. - Google Patents

Composiciones de trofinetida.

Info

Publication number
MX2022001505A
MX2022001505A MX2022001505A MX2022001505A MX2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A MX 2022001505 A MX2022001505 A MX 2022001505A
Authority
MX
Mexico
Prior art keywords
compositions
compounds
trofinetide
products
methods
Prior art date
Application number
MX2022001505A
Other languages
English (en)
Spanish (es)
Inventor
Clive Blower
Mathew Peterson
James Murray Shaw
James Anthony Bonnar
Etienne David Frank Philippe Moniotte
Martin Bernard Catherine Bousmanne
Cecilia Betti
Karel Willy Luc Decroos
Mimoun Ayoub
Original Assignee
Neuren Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd filed Critical Neuren Pharmaceuticals Ltd
Publication of MX2022001505A publication Critical patent/MX2022001505A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/06Silicon, titanium, zirconium or hafnium; Oxides or hydroxides thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J21/00Catalysts comprising the elements, oxides, or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium, or hafnium
    • B01J21/18Carbon
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022001505A 2019-08-05 2020-08-03 Composiciones de trofinetida. MX2022001505A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Publications (1)

Publication Number Publication Date
MX2022001505A true MX2022001505A (es) 2022-03-11

Family

ID=74502416

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001505A MX2022001505A (es) 2019-08-05 2020-08-03 Composiciones de trofinetida.

Country Status (16)

Country Link
US (3) US11370755B2 (https=)
EP (1) EP4009962A4 (https=)
JP (2) JP2022543391A (https=)
KR (1) KR20220059479A (https=)
CN (1) CN114667136A (https=)
AU (1) AU2020324396B2 (https=)
BR (1) BR112022002229A2 (https=)
CA (1) CA3149633A1 (https=)
CL (1) CL2022000301A1 (https=)
CO (1) CO2022002616A2 (https=)
IL (1) IL290324A (https=)
JO (1) JOP20220027A1 (https=)
MX (1) MX2022001505A (https=)
MY (1) MY206115A (https=)
SA (1) SA522431585B1 (https=)
WO (1) WO2021026066A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물
IL310045A (en) * 2021-07-12 2024-03-01 Acadia Pharm Inc Crystalline forms of tropintide
WO2025169163A1 (en) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Method for the synthesis of trofinetide and its analogues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573765B1 (fr) * 1984-11-23 1988-06-10 Solvay Procede pour la synthese de peptides
WO2006127702A2 (en) * 2005-05-23 2006-11-30 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
JP5220724B2 (ja) 2006-03-14 2013-06-26 ニューレン ファーマシューティカルズ リミテッド グリシル−2−メチルプロリルグルタミン酸塩の経口製剤
EP2060580A1 (en) * 2007-11-19 2009-05-20 SOLVAY (Société Anonyme) Process for the manufacture of persilylated peptides
US9708366B2 (en) * 2011-01-27 2017-07-18 Neuren Pharmaceuticals Ltd. Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물

Also Published As

Publication number Publication date
KR20220059479A (ko) 2022-05-10
SA522431585B1 (ar) 2025-02-13
WO2021026066A1 (en) 2021-02-11
EP4009962A1 (en) 2022-06-15
US20240109841A1 (en) 2024-04-04
AU2020324396A1 (en) 2022-03-10
US12297172B2 (en) 2025-05-13
CN114667136A (zh) 2022-06-24
AU2020324396B2 (en) 2025-07-03
BR112022002229A2 (pt) 2022-04-19
JP2022543391A (ja) 2022-10-12
EP4009962A4 (en) 2023-08-09
IL290324A (en) 2022-04-01
US11370755B2 (en) 2022-06-28
MY206115A (en) 2024-11-29
JOP20220027A1 (ar) 2023-01-30
JP2026063085A (ja) 2026-04-10
US11866406B2 (en) 2024-01-09
US20220324799A1 (en) 2022-10-13
US20220055987A1 (en) 2022-02-24
CA3149633A1 (en) 2021-02-11
CL2022000301A1 (es) 2022-09-20
CO2022002616A2 (es) 2022-06-10

Similar Documents

Publication Publication Date Title
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2018002505A1 (es) Inhibidores del envejecimiento proteico-proteico wdr5
CO2022002616A2 (es) Composiciones de trofinetida
CO2021006672A2 (es) Moduladores de nlrp3
PH12020551062A1 (en) 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
UY39011A (es) Métodos para purificar cannabinoides, composiciones y kits de estos
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
BR112018014015A2 (pt) derivados de tioidantoína substituídos como antagonistas do receptor de androgênio
MX2019000980A (es) Compuestos y composiciones y usos de los mismos.
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
CL2020002275A1 (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y.
BR112017024243A2 (pt) Sal de (s)-csa de s-cetamina, sal de (r)-csa de s- cetamina e processos para a preparação de s- cetamina
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
NI202100020A (es) Inhibidores de pde4 que contienen boro
NI201801172A (es) Nuevos compuestos para el tratamiento de enfermedades parasitarias
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
CL2020001093A1 (es) Proceso para preparar el benzotiofen-2-il boronato.
CL2021003557A1 (es) Moduladores del receptor de nmda.
AR130483A1 (es) Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
EP4537831A3 (de) Pharmazeutische zusammensetzungen mit anti-rankl-antikörpern, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzämien
BR112018076443A2 (pt) formas cristalinas de um composto de triazolopirimidina